S100P expression in ductal type of carcinoma ex pleomorphic adenoma

American Journal of Surgical Pathology

Volumn 35, Issue 3, 2011, Pages 346-355

  Hashimoto, Kazuki ^a   Yamamoto, Hidetaka ^a   Shiratsuchi, Hideki ^a   Nakashima, Torahiko ^a   Tamiya, Sadafumi ^a   Higaki, Yuichiro ^b   Komune, Shizuo ^a   Tsuneyoshi, Masazumi ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

androgen receptor; carcinoma ex pleomorphic adenoma; HER2 neu; S100P; Salivary gland

Indexed keywords

ANDROGEN RECEPTOR; CALCIUM BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53; S100P PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PAROTID GLAND TUMOR; PATHOLOGY; PLEOMORPHIC ADENOMA;

ADENOMA, PLEOMORPHIC; ADULT; AGED; CALCIUM-BINDING PROTEINS; CARCINOMA, DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PAROTID NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953030559     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31820832a6     Document Type: Article

References (37)

1. Altemani A, Martins MT, Freitas L, et al. Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005;46:635-641. (Pubitemid 40834822)
2. Amler LC, Agus DB, LeDuc C, et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000;60:6134-6141.
3. Arumugam T, Simeone DM, Van Golen K, et al. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 2005;11:5356-5364. (Pubitemid 41060808)
4. Auclair PL, Ellis GL. Atypical features in salivary gland mixed tumors: their relationship to malignant transformation. ModPathol. 1996;9:652-657. (Pubitemid 26227567)
5. Basu GD, Azorsa DO, Kiefer JA, et al. Functional evidence implicating S100P in prostate cancer progression. Int J Cancer. 2008;123:330-339. (Pubitemid 351842017)
6. Becker T, Gerke V, Kube E, et al. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 1992;207: 541-547.
7. Brandwein-Gensler MS, Skalova A, Nagao T. Salivary duct carcinoma. In: Barnes L, Eveson JW, Reichart P, et al. eds. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005: 236-237.
8. Cheuk W, Chan JK. Advances in salivary gland pathology. Histopathology. 2007;51:1-20. (Pubitemid 46976367)
9. Cheuk W, Chan JKC. Salivary gland tumors. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 3rd Edition. London: Churchill Livingstone; 2007:239-326.
10. DeRoche TC, Hoschar AP, Hunt JL. Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas. Arch Pathol Lab Med. 2008;132:1907-1911.
11. Di Palma S, Skalova A, Van?eek T, et al. Non-invasive (intracap-sular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology. 2005;46:144-152. (Pubitemid 40293012)
12. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637-668. (Pubitemid 32520962)
13. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expres-sion of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81-92. (Pubitemid 40051662)
14. Ellis GL, Auclair PL. Carcinoma Ex Pleomorphic Adenoma. In: Steven GS, ed. Atlas of Tumor Pathology. Tumors of the Salivary Glands, Fourth Series. Washington (DC): Armed Forces Institute of Pathology; 2008:259-269.
15. Freitas LL, Araujo VC, Martins MT, et al. Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcino-matous transformation. Int J Surg Pathol. 2005;13:337-342. (Pubitemid 41688595)
16. Gibadulinova A, Tothova V, Pastorek J, et al. Transcriptional regulation and functional implication of S100P in cancer. Amino Acids. 2010.
17. Gnepp DR. Malignant mixed tumors of the salivary glands: a review. Pathol Annu. 1993;28:279-328.
18. Gnepp DR, Brandwein-Gensler MS, El-Naggar AK, et al. Carcinoma ex pleomorphic adenoma. In: Barnes L, Eveson JW, Reichart P, et al, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005:242-243.
19. Guerreiro Da Silva ID, Hu YF, Russo IH, et al. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol. 2000;16:231-240.
20. Ihrler S, Weiler C, Hirschmann A, et al. Intraductal carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with dysfunctional p53. Histopathology. 2007;51: 362-371. (Pubitemid 47301606)
21. Koltzscher M, Neumann C, Konig S, et al. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell. 2003;14:2372-2384. (Pubitemid 36724327)
22. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of73 cases. Hum Pathol. 2001;32:596-604. (Pubitemid 32601241)
23. Li R, Wheeler T, Dai H, et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004;28: 928-934. (Pubitemid 38856850)
24. Li X, Tsuji T, Wen S, et al. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridiza-tion in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer. 1997;79: 2314-2319. (Pubitemid 27251013)
25. Lin F, Shi J, Liu H, et al. Diagssssnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78-91.
26. Matsubayashi S, Yoshihara T. Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study. Eur Arch Otorhinolaryngol. 2007;264:789-795. (Pubitemid 46817491)
27. Nakajima Y, Kishimoto T, Nagai Y, et al. Expressions of androgen receptor and its co-regulators in carcinoma ex pleomorphic adenoma of salivary gland. Pathology. 2009;41:634-639.
28. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801-806. (Pubitemid 37047840)
29. Ohuchida K, Mizumoto K, Egami T, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res. 2006;12:5411-5416. (Pubitemid 44497255)
30. Press MF, Pike MC, Hung G, et al. Amplification and over-expression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675-5682. (Pubitemid 24346266)
31. Rehbein G, Simm A, Hofmann HS, et al. Molecular regulation of S100P in human lungadenocarcinomas. Int J Mol Med. 2008;22:69-77.
32. Rosa JC, Fonseca I, Felix A, et al. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology. 1996;28:247-252. (Pubitemid 26088731)
33. Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohisto-chemistry. Histopathology. 2003;42:348-356. (Pubitemid 36459812)
34. Takeda Y. An immunohistochemical study of bizarre neoplastic cells in pleomorphic adenoma: its cytological nature and prolif-erative activity. Pathol Int. 1999;49:993-999. (Pubitemid 30043139)
35. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. JClinOncol. 1992;10:1044-1048.
36. Wang G, Platt-Higgins A, Carroll J, et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006;66:1199-1207. (Pubitemid 43165991)
37. Yamamoto H, Uryu H, Segawa Y, et al. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland. Pathol Int. 2008;58:322-326. (Pubitemid 351579645)